Amgen Trial Fails To Show Benefit Of Anemia Drug In Heart Failure Patients
The RED-HF (Reduction of Events With Darbepoetin Alfa in Heart Failure) Trial, which started in 2006, had randomized 2,278 patients with heart failure and anemia to receive either Aranesp or placebo. Patients in the trial started with hemoglobin levels ...
Amgen Announces Top-Line Results Of Phase 3 Aranesp (darbepoetin alfa ...PharmaLive (press release) (subscription)
Amgen' Anemia Drug Aranesp Fails To Meet Primary Endpoint - Quick FactsRTT News
Amgen's Aranesp for Anemia Fails to Help Heart PatientsBloomberg

all 15 news articles »